1. ICH Harmonized Tripartite Guideline, Pharmaceutical development, Q8 (R2), August 2009.
2. ICH Harmonized Tripartite Guideline, Quality risk management, Q9, September 2006.
3. ICH Harmonized Tripartite Guideline, Pharmaceutical quality system, Q10, February 2010.
4. ICH Harmonized Tripartite Guideline, Development and manufacture of drug substances (chemical entities and biotechnological/biological entities), Q11, July 2014.
5. A-Mab A case study in bioprocess development, CMC biotech working group, October 2009.